Becknell, B. & Caligiuri, M. A. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv. Immunol. 86, 209–239 (2005).
Vidal, R. L. & Hetz, C. Unspliced XBP1 controls autophagy through FoxO1. Cell Res. 23, 463–464 (2013).
Calfon, M. et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature 415, 92–96 (2002).
Uemura, A., Oku, M., Mori, K. & Yoshida, H. Unconventional splicing of XBP1 mRNA occurs in the cytoplasm during the mammalian unfolded protein response. J. Cell Sci. 122, 2877–2886 (2009).
Clauss, I. M., Chu, M., Zhao, J. L. & Glimcher, L. H. The basic domain/leucine zipper protein hXBP-1 preferentially binds to and transactivates CRE-like sequences containing an ACGT core. Nucleic Acids Res. 24, 1855–1864 (1996).
Bettigole, S. E. et al. The transcription factor XBP1 is selectively required for eosinophil differentiation. Nat. Immunol. 16, 829–837 (2015).
Kamimura, D. & Bevan, M. J. Endoplasmic reticulum stress regulator XBP-1 contributes to effector CD8+ T cell differentiation during acute infection. J. Immunol. 181, 5433–5441 (2008).
Shaffer, A. L. et al. XBP1, downstream of Blimp-1, expands the secretory apparatus and other organelles, and increases protein synthesis in plasma cell differentiation. Immunity 21, 81–93 (2004).
Cubillos-Ruiz, J. R. et al. ER stress sensor XBP1 controls anti-tumor immunity by disrupting dendritic cell homeostasis. Cell 161, 1527–1538 (2015).
Sadighi Akha, A. A. et al. Heightened induction of proapoptotic signals in response to endoplasmic reticulum stress in primary fibroblasts from a mouse model of longevity. J. Biol. Chem. 286, 30344–30351 (2011).
Cross, B. C. et al. The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule. Proc. Natl Acad. Sci. USA 109, E869–E878 (2012).
Mai, B. & Breeden, L. Xbp1, a stress-induced transcriptional repressor of the Saccharomyces cerevisiae Swi4/Mbp1 family. Mol. Cell. Biol. 17, 6491–6501 (1997).
Glimcher, L. H., Townsend, M. J., Sullivan, B. M. & Lord, G. M. Recent developments in the transcriptional regulation of cytolytic effector cells. Nat. Rev. Immunol. 4, 900–911 (2004).
Townsend, M. J. et al. T-bet regulates the terminal maturation and homeostasis of NK and Vα14i NKT cells. Immunity 20, 477–494 (2004).
Chen, X. et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature 508, 103–107 (2014).
Acosta-Alvear, D. et al. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol. Cell 27, 53–66 (2007).
Verdeil, G., Puthier, D., Nguyen, C., Schmitt-Verhulst, A. M. & Auphan-Anezin, N. STAT5-mediated signals sustain a TCR-initiated gene expression program toward differentiation of CD8 T cell effectors. J. Immunol. 176, 4834–4842 (2006).
Gotthardt, D. et al. STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 6, 414–429 (2016).
Jahrsdorfer, B. et al. Granzyme B produced by human plasmacytoid dendritic cells suppresses T-cell expansion. Blood 115, 1156–1165 (2010).
Romero-Ramirez, L. et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer Res. 64, 5943–5947 (2004).
Gupta, S. et al. HSP72 protects cells from ER stress-induced apoptosis via enhancement of IRE1α-XBP1 signaling through a physical interaction. PLoS Biol. 8, e1000410 (2010).
Carson, W. E. et al. A potential role for interleukin-15 in the regulation of human natural killer cell survival. J. Clin. Invest. 99, 937–943 (1997).
Yano, S., Komine, M., Fujimoto, M., Okochi, H. & Tamaki, K. Interleukin 15 induces the signals of epidermal proliferation through ERK and PI 3-kinase in a human epidermal keratinocyte cell line, HaCaT. Biochem. Biophys. Res. Commun. 301, 841–847 (2003).
Wang, Y. et al. PI3K inhibitor LY294002, as opposed to wortmannin, enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells. Int. J. Oncol. 50, 606–612 (2017).
Kohn, A. D., Takeuchi, F. & Roth, R. A. Akt, a pleckstrin homology domain containing kinase, is activated primarily by phosphorylation. J. Biol. Chem. 271, 21920–21926 (1996).
McKeehan, W. & Hardesty, B. The mechanism of cycloheximide inhibition of protein synthesis in rabbit reticulocytes. Biochem. Biophys. Res. Commun. 36, 625–630 (1969).
Rock, K. L. et al. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78, 761–771 (1994).
Zambricki, E. et al. Signaling T-cell survival and death by IL-2 and IL-15. Am. J. Transplant. 5, 2623–2631 (2005).
Xu, D. et al. Phosphorylation and activation of ubiquitin-specific protease-14 by Akt regulates the ubiquitin-proteasome system. eLife 4, e10510 (2015).
Lee, M. S. et al. PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat. Commun. 6, 7769 (2015).
Guo, H., Samarakoon, A., Vanhaesebroeck, B. & Malarkannan, S. The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation. J. Exp. Med. 205, 2419–2435 (2008).
Tassi, I. et al. p110γ and p110δ phosphoinositide 3-kinase signaling pathways synergize to control development and functions of murine NK cells. Immunity 27, 214–227 (2007).
Ali, K. et al. Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer. Nature 510, 407–411 (2014).
Nandagopal, N., Ali, A. K., Komal, A. K. & Lee, S. H. The critical role of IL-15–PI3K–mTOR pathway in natural killer cell effector functions. Front. Immunol. 5, 187 (2014).
Zebedin, E. et al. Leukemic challenge unmasks a requirement for PI3Kδ in NK cell-mediated tumor surveillance. Blood 112, 4655–4664 (2008).
Liu, Y. et al. Preventing oxidative stress: a new role for XBP1. Cell Death Differ. 16, 847–857 (2009).
Jiang, S., Munker, R. & Andreeff, M. Bcl-2 is expressed in human natural killer cells and is regulated by interleukin-2. Nat. Immunol. 15, 312–317 (1996).
Viant, C. et al. Cell cycle progression dictates the requirement for BCL2 in natural killer cell survival. J. Exp. Med. 214, 491–510 (2017).
Minagawa, M. et al. Enforced expression of Bcl-2 restores the number of NK cells, but does not rescue the impaired development of NKT cells or intraepithelial lymphocytes, in IL-2/IL-15 receptor β-chain-deficient mice. J. Immunol. 169, 4153–4160 (2002).
Chu, J. et al. CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma. Leukemia 28, 917–927 (2014).
Meinke, S. & Watzl, C. NK cell cytotoxicity mediated by 2B4 and NTB-A is dependent on SAP acting downstream of receptor phosphorylation. Front. Immunol. 4, 3 (2013).
Chu, J. et al. Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells. Clin. Cancer Res. 20, 3989–4000 (2014).
Deng, Y. et al. Transcription factor Foxo1 is a negative regulator of natural killer cell maturation and function. Immunity 42, 457–470 (2015).
Wang, Y. et al. CGK733-induced LC3 II formation is positively associated with the expression of cyclin-dependent kinase inhibitor p21Waf1/Cip1 through modulation of the AMPK and PERK/CHOP signaling pathways. Oncotarget 6, 39692–39701 (2015).
Wang, Y. et al. PERK/CHOP contributes to the CGK733-induced vesicular calcium sequestration which is accompanied by non-apoptotic cell death. Oncotarget 6, 25252–25265 (2015).
Yu, J. et al. Pro- and antiinflammatory cytokine signaling: reciprocal antagonism regulates interferon-γ production by human natural killer cells. Immunity 24, 575–590 (2006).